Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -4.05 | Insider Own | 10.72% | Shs Outstand | 60.14M | Perf Week | -1.96% |
| Market Cap | 300.68M | Forward P/E | - | EPS next Y | -0.87 | Insider Trans | -5.34% | Shs Float | 53.84M | Perf Month | -21.63% |
| Enterprise Value | 244.80M | PEG | 0.01 | EPS next Q | - | Inst Own | - | Short Float | 13.35% | Perf Quarter | -21.75% |
| Income | -274.43M | P/S | 1.39 | EPS this Y | 40.43% | Inst Trans | - | Short Ratio | 7.07 | Perf Half Y | -30.84% |
| Sales | 215.72M | P/B | 1.37 | EPS next Y | 63.83% | ROA | -66.64% | Short Interest | 7.19M | Perf YTD | -43.31% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -84.95% | 52W High | 9.98 -49.70% | Perf Year | 18.48% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -74.73% | 52W Low | 4.16 20.77% | Perf 3Y | -9.09% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -5.26% -2.73% | Gross Margin | 92.82% | Volatility | 6.78% 4.61% | Perf 5Y | -69.34% |
| Dividend TTM | - | EV/Sales | 1.13 | EPS Y/Y TTM | -1165.62% | Oper. Margin | -86.07% | ATR (14) | 0.27 | Perf 10Y | -56.52% |
| Dividend Ex-Date | - | Quick Ratio | 1.60 | Sales Y/Y TTM | 9.55% | Profit Margin | -127.41% | RSI (14) | 35.03 | Recom | 2.37 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.61 | EPS Q/Q | -64.00% | SMA20 | -6.33% | Beta | 0.61 | Target Price | 21.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | 4.00% | SMA50 | -13.85% | Rel Volume | 1.36 | Prev Close | 5.00 |
| Employees | 533 | LT Debt/Eq | 0.02 | Earnings | Nov 04 | SMA200 | -23.32% | Avg Volume | 959.47K | Price | 5.02 |
| IPO Date | Apr 12, 2006 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -19.19% -5.93% | Net Debt/EBITDA | 0.34 | Volume | 1,306,481 | Change | 0.40% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-11-26 | Reiterated | HC Wainwright & Co. | Buy | |
| Feb-23-26 | Reiterated | HC Wainwright & Co. | Buy | |
| Jan-05-26 | Reiterated | HC Wainwright & Co. | Buy | |
| Dec-31-25 | Reiterated | Jefferies | Hold | $7.50 |
| Nov-05-25 | Reiterated | B.Riley Financial | $11 | |
| Jul-11-24 | Initiated | Cantor Fitzgerald | Overweight | $11 |
| Feb-25-22 | Downgrade | Jefferies | Buy → Hold | |
| Jan-14-21 | Downgrade | Citigroup | Buy → Neutral | |
| Oct-29-20 | Upgrade | Citigroup | Neutral → Buy | |
| Jun-09-20 | Downgrade | Citigroup | Buy → Neutral |
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 216 | 216 | 199 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 16 | 13 | 11 | — | — | — | — | — | — | |
| Gross Profit | 200 | 203 | 187 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 263 | 238 | 146 | — | — | — | — | — | — | |
| Research and Development | 117 | 109 | 74 | — | — | — | — | — | — | |
| Other Operating Expense | 7 | 7 | 8 | — | — | — | — | — | — | |
| Operating Income | -185 | -151 | -41 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 13 | 18 | — | — | — | — | — | — | |
| Net Income Before Taxes | -176 | -139 | -23 | — | — | — | — | — | — | |
| Income Taxes | 97 | 82 | -4 | — | — | — | — | — | — | |
| Consolidated Net Income | -276 | -220 | -19 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -276 | -220 | -19 | — | — | — | — | — | — | |
| Net Income | -276 | -220 | -19 | — | — | — | — | — | — | |
| EPS (Recurring) | -4.63 | -3.74 | -0.32 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -4.63 | -3.74 | -0.32 | — | — | — | — | — | — | |
| EPS (Diluted) | -4.63 | -3.74 | -0.32 | — | — | — | — | — | — | |
| EBITDA | -166 | -127 | -15 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.39 | 2.41 | 1.40 | — | — | — | — | — | — | |
| Gross Margin | 92.59 | 93.98 | 93.97 | — | — | — | — | — | — | |
| Operating Margin | -85.65 | -69.91 | -20.60 | — | — | — | — | — | — | |
| Net Margin | -127.78 | -101.85 | -9.55 | — | — | — | — | — | — | |
| Shares Outstanding | 60 | 59 | 58 | — | — | — | — | — | — | |
| Market Capitalization | 301 | 520 | 278 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Williams Timothy | SVP & General Counsel | Mar 02 '26 | Sale | 8.27 | 42,434 | 350,755 | 377,450 | Mar 04 |
| Moran Kevin Patrick | SVP, CFO & Treasurer | Mar 02 '26 | Sale | 8.27 | 42,442 | 350,821 | 411,380 | Mar 04 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer | Mar 02 '26 | Sale | 8.27 | 30,800 | 254,590 | 333,469 | Mar 04 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | Mar 02 '26 | Sale | 8.17 | 156,235 | 1,276,971 | 2,704,496 | Mar 04 |
| Birznieks Gunther | SVP, Business Development | Mar 02 '26 | Sale | 8.27 | 42,431 | 350,730 | 494,197 | Mar 04 |
| Honore Tage | Director | Feb 23 '26 | Sale | 8.03 | 30,000 | 240,900 | 93,469 | Feb 24 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | Aug 07 '25 | Buy | 4.15 | 10,000 | 41,500 | 2,335,731 | Aug 08 |
| Mitchell Stephen Ray | Director | Jun 13 '25 | Sale | 4.59 | 7,000 | 32,130 | 97,082 | Jun 16 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | May 21 '25 | Buy | 4.40 | 10,000 | 43,996 | 2,325,731 | May 21 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | May 16 '25 | Buy | 4.22 | 20,000 | 84,472 | 2,315,731 | May 19 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | Mar 06 '25 | Buy | 5.01 | 10,000 | 50,150 | 2,295,731 | Mar 06 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | Mar 05 '25 | Buy | 5.02 | 10,000 | 50,200 | 2,285,731 | Mar 05 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | Mar 03 '25 | Buy | 4.71 | 10,000 | 47,050 | 2,275,731 | Mar 04 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | Feb 28 '25 | Buy | 4.76 | 10,000 | 47,600 | 2,361,730 | Feb 28 |
| Polymeropoulos Mihael Hristos | director, officer, other: President and CEO | Feb 27 '25 | Buy | 4.76 | 10,000 | 47,600 | 2,351,730 | Feb 27 |